Romidepsin

DCTPepD ID  DCTPepD0027

Active Ingredients   Romidepsin

Description  A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.

Synonyms  Antibiotic FR 901228; Depsipeptide; FK228; FR901228; Istodax; L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide; N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic; Romidepsin

Disease  Cutaneous T Cell Lymphomas (CTCL)

Classification

  

HDAC inhibitor Peptide and derivative Cyclic

Structure Information


Molecular Formula  C24H36N4O6S2

Molecular Weight  540.7

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (1S,4S,7Z,10S,16Z,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

InChI  InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17?,19-,20+/m1/s1

InChI_Key OHRURASPPZQGQM-KXOYPWAYSA-N

SMILES  C/C=C(C(N[C@@H](C(C)C)C(O[C@H]1CC2=O)=O)=O)\NC(C(CSSCC/C=C/1)NC([C@H](N2)C(C)C)=O)=O

External Codes


PubChem CID  57515973

DrugBank Accession Number  DB06176

NCI Thesaurus Code  C1544  

UNII  CX3T89XQBK   GSRS

CAS  128517-07-7



Drug approval


Drug indication
    Romidepsin is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.

Drug Name Strength Dosage Form/Route Company Marketing Status Drug ID Approval year
Istodax 10mg/vial Powder; Intravenous Celgene Prescription NDA: 022393 2009
Romidepsin 10mg/vial Powder; Intravenous Fresenius Kabi Usa Prescription ANDA: 206254 2021
Romidepsin 10mg/2ml (5mg/ml) Solution; Intravenous Teva Pharms Usa Inc Prescription NDA: 208574 2020
Romidepsin 27.5mg/5.5ml (5mg/ml) Solution; Intravenous Teva Pharms Usa Inc Prescription NDA: 208574 2020
Istodax 10 mg / vial Powder For Solution, Kit; Intravenous Celgene Inc Prescription DIN: 02414295 2014

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT03770000 An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma T Cell Lymphoma Phase 1/2 Treatment
NCT01537744 Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma Solid Tumors; Virally Mediated Cancers and Liposarcoma Phase 1 Treatment
NCT01353664 An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols Lymphoma; Cancer Phase 2 Treatment
NCT01913119 A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Histologically Proven Extranodal NKTcell Lymphoma Early Phase 1 Treatment
NCT03355768 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Lymphoma, T-Cell, Peripheral Phase 3 Other

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.